Tier 3 includes rare variants reported in genes in a broader set of cancer susceptibility panels not currently associated with sarcoma, e.g. BRCA1. Tier 3 variants are reviewed by clinical scientists, but only discussed at GTAB and actioned if pertinent to the patient's disease type or their family's cancer history, such as NF1 germline alterations detected in individuals with MPNST (see supplementary material, Table S1). This evidence concerns the gene BRCA1 and sarcoma.